Brahm H Segal

13PUBLICATIONS
86CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 28, 2026
Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.

|Jul 07, 2025
Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients.

Lauren Polyakov, Angelina Lim, Alexandra Meyer

|Jan 25, 2025
Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy.

Ryutaro Kajihara, Mark D Long, Toshifumi Hoki

|Dec 05, 2024
Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer.

Spencer R Rosario, Mark D Long, Shanmuga Chilakapati

|May 04, 2024
The implications of APOBEC3-mediated C-to-U RNA editing for human disease.

Melissa Van Norden, Zackary Falls, Sapan Mandloi

|Jun 23, 2023
Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.

Joy Sarkar, Eduardo Cortes Gomez, Takaaki Oba

Pageof 3

Frequent Collaborators

5 joint publications

Fumito Ito

3 joint publications

Eduardo Cortes Gomez

3 joint publications

Hongbin Chen

3 joint publications

Ryutaro Kajihara